Table 1.

Summary of molecular targeted drugs used in non-GIST STS, their targets and class-specific drug toxicities

Molecular targeted drug	Mechanism of action	Soft tissue sarcoma	Class-specific drug toxicities
Imatinib mesylate	Inhibits ABL, c-KIT, PDGF, CSF1 kinases	Aggressive fibromatosis, dermatofibrosarcoma protuberans, pigmented villonodular synovitis	Fluid retention
Tyrosine kinase inhibitors and antibodies (non-imatinib)	Inhibit VEGF, PDGF, Src kinases	Leiomyosarcoma, solitary fibrous tumor, synovial sarcoma	Hepatobiliary, pancreatic and bowel-related complications, thromboembolic phenomena, pleural effusions (dasatinib)
mTOR inhibitors	Inhibit the PI3K-AKT-mTOR pathway	PEComa	Non-infectious pneumonitis, acute cholecystitis
Trabectedin	Unknown (probably inactivates FUS-CHOP oncogene)	Myxoid liposarcoma, leiomyosarcoma	Capillary leak syndrome

GIST, gastrointestinal stromal tumor; STS, soft tissue sarcoma; VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor; CSF1, colony-stimulating factor 1.